Neurogene (NGNE) Total Current Liabilities (2013 - 2026)
Neurogene's (NGNE) quarterly Total Current Liabilities came in at $18.9 million in Q1 2026, up 33.86% YoY from $14.1 million in Q1 2025, and up 14.96% on a QoQ basis from $16.4 million in Q4 2025.
Neurogene (NGNE) Total Current Liabilities (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Total Current Liabilities data on file, last reported at $18.9 million in Q1 2026.
- Quarterly Total Current Liabilities rose 33.86% year-over-year to $18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.9 million (up 33.86% YoY) and the FY2025 annual result came in at $16.4 million, up 8.27% from the prior year.
- Total Current Liabilities climbed to $18.9 million in Q1 2026, from $16.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $23.0 million in Q4 2023 to a low of $4.9 million in Q2 2023.
- A 5-year average of $12.3 million and a median of $13.1 million in 2024 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 245.41% in 2023, down 49.09% in 2023.
- Tracing NGNE's Total Current Liabilities over 5 years: stood at $6.7 million in 2022, then surged by 245.41% to $23.0 million in 2023, then plunged by 34.02% to $15.2 million in 2024, then advanced by 8.27% to $16.4 million in 2025, then rose by 14.96% to $18.9 million in 2026.
- The last three Total Current Liabilities figures came in at $18.9 million (Q1 2026), $16.4 million (Q4 2025), and $14.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 21.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.51 Mn |
| Mar 31, 2026 | 18.87 Mn |
| Dec 31, 2025 | 16.41 Mn |
| Sep 30, 2025 | 14.71 Mn |
| Jun 30, 2025 | 15.44 Mn |
| Mar 31, 2025 | 14.09 Mn |
| Dec 31, 2024 | 15.16 Mn |
| Sep 30, 2024 | 15.80 Mn |
| Jun 30, 2024 | 13.07 Mn |
| Mar 31, 2024 | 11.82 Mn |
| Dec 31, 2023 | 22.97 Mn |
| Sep 30, 2023 | 5.21 Mn |
| Jun 30, 2023 | 4.88 Mn |
| Mar 31, 2023 | 7.16 Mn |
| Dec 31, 2022 | 6.65 Mn |
| Sep 30, 2022 | 10.24 Mn |
| Jun 30, 2022 | 9.27 Mn |
| Mar 31, 2022 | 7.60 Mn |
| Dec 31, 2021 | 8.64 Mn |
| Sep 30, 2021 | 9.00 Mn |